`
`
`
`DEPARTMENT OF HEALTH AND HUMAN SERVICES
`
`
`
`
`
`
`Food and Drug Administration
`Silver Spring MD 20993
`
`
`
`
`
`
`NDA 201023/S-019
`
`SUPPLEMENT APPROVAL
`FULFILLMENT OF POSTMARKETING REQUIREMENTS
`
`
`
`Sanofi-Aventis U.S. LLC
`Attention: Sunil Gupta, MD
`Associate Vice President, Global Regulatory Affairs
`55 Corporate Dr., Mail Stop 55C-205A
`Bridgewater, NJ 08807
`
`
`Dear Dr. Gupta:
`
`Please refer to your Supplemental New Drug Application (sNDA) dated November 14, 2016,
`received November 14, 2016, and your amendments, submitted under section 505(b) of the
`Federal Food, Drug, and Cosmetic Act (FDCA) for Jevtana® (cabazitaxel), Injection,
`60 mg/1.5 mL.
`
`This Prior Approval supplemental new drug application provides for revisions to the Dosage and
`Administration, Adverse Reactions, and Clinical Studies sections of the Full Prescribing
`Information based on data contained in two final clinical study reports for studies FIRSTANA
`(EFC 11784) and PROSELICA (EFC 11785). The supplement also proposes to fulfill PMRs
`1649-3 and 1649-4 from the June 17, 2010 approval letter.
`
`APPROVAL & LABELING
`
`We have completed our review of this supplemental application, as amended. It is approved,
`effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling
`text.
`
`CONTENT OF LABELING
`
`As soon as possible, but no later than 14 days from the date of this letter, submit the content of
`labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA
`automated drug registration and listing system (eLIST), as described at
`http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content
`of labeling must be identical to the enclosed labeling (text for the package insert and text for the
`patient package insert), with the addition of any labeling changes in pending “Changes Being
`Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed
`labeling.
`
`
`Reference ID: 4152597
`
`

`

`NDA 201023/S-019
`Page 2
`
`Information on submitting SPL files using eList may be found in the guidance for industry titled
`“SPL Standard for Content of Labeling Technical Qs and As” at
`http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/U
`CM072392.pdf.
`
`The SPL will be accessible from publicly available labeling repositories.
`
`Also within 14 days, amend all pending supplemental applications that include labeling changes
`for this NDA, including CBE supplements for which FDA has not yet issued an action letter,
`with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the
`changes approved in this supplemental application, as well as annual reportable changes and
`annotate each change. To facilitate review of your submission, provide a highlighted or marked-
`up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy
`should provide appropriate annotations, including supplement number(s) and annual report
`date(s).
`
`REQUIRED PEDIATRIC ASSESSMENTS
`
`Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new
`active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of
`administration are required to contain an assessment of the safety and effectiveness of the
`product for the claimed indication(s) in pediatric patients unless this requirement is waived,
`deferred, or inapplicable.
`
`Because none of these criteria apply to your application, you are exempt from this requirement.
`
`FULFILLMENT OF POSTMARKETING REQUIREMENTS
`
`We have received your submission dated November 14, 2016, containing the final reports for the
`following postmarketing requirements listed in the June 17, 2010, approval letter.
`
`
`1649-3:
`
`Conduct a Phase 3 randomized controlled trial in patients with hormone-
`refractory metastatic prostate cancer comparing 75 mg/m2 docetaxel with
`prednisone with cabazitaxel 25 mg/m2 with prednisone and cabazitaxel
`20 mg/m2 with prednisone as first-line therapy. The primary endpoint
`should be overall survival to evaluate the incidence of drug-related death
`as well as efficacy. The trial should be powered to detect a 25%
`difference in overall survival. The trial will include interim analyses for
`evaluation of efficacy based on overall survival and safety of the
`25 mg/m2 with prednisone arm versus the 20 mg/m2 with prednisone arm
`to potentially drop one of the cabazitaxel arms. Submit the protocol for
`agency review prior to commencing the trial.
`
`
`
`
`
`
`
`Reference ID: 4152597
`
`

`

`NDA 201023/S-019
`Page 3
`
`
`1649-4:
`
`Conduct a Phase 3 randomized controlled trial in 1222 patients with
`hormone-refractory metastatic prostate cancer previously treated with
`docetaxel comparing cabazitaxel 20 mg/m2 with prednisone versus
`cabazitaxel 25 mg/m2 with prednisone and powered to preserve 50% of the
`treatment effect of cabazitaxel 25 mg/m2. The study will include interim
`analyses for evaluation of drug-related deaths and safety as well as overall
`survival of the cabazitaxel 25 mg/m2 with prednisone arm versus the
`cabazitaxel 20 mg/m2 with prednisone arm to potentially discontinue the
`trial. Submit the protocol for agency review prior to commencing the trial.
`
`
`We have reviewed your submission and conclude that the above requirements were fulfilled.
`
`This completes all of your postmarketing requirements and postmarketing commitments
`acknowledged in our June 17, 2010, letter.
`
`PROMOTIONAL MATERIALS
`
`You may request advisory comments on proposed introductory advertising and promotional
`labeling. To do so, submit the following, in triplicate, (1) a cover letter requesting advisory
`comments, (2) the proposed materials in draft or mock-up form with annotated references, and
`(3) the package insert(s) to:
`
`
`OPDP Regulatory Project Manager
`Food and Drug Administration
`Center for Drug Evaluation and Research
`Office of Prescription Drug Promotion (OPDP)
`5901-B Ammendale Road
`Beltsville, MD 20705-1266
`
`
`Alternatively, you may submit a request for advisory comments electronically in eCTD format.
`For more information about submitting promotional materials in eCTD format, see the draft
`Guidance for Industry (available at:
`http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/U
`CM443702.pdf).
`
`You must submit final promotional materials and package insert(s), accompanied by a Form
`FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form
`FDA 2253 is available at
`http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf.
`Information and Instructions for completing the form can be found at
`http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf. For
`more information about submission of promotional materials to the Office of Prescription Drug
`Promotion (OPDP), see http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm.
`
`All promotional materials that include representations about your drug product must be promptly
`revised to be consistent with the labeling changes approved in this supplement, including any
`
`Reference ID: 4152597
`
`

`

`NDA 201023/S-019
`Page 4
`
`new safety information [21 CFR 314.70(a)(4)]. The revisions in your promotional materials
`should include prominent disclosure of the important new safety information that appears in the
`revised package labeling. Within 7 days of receipt of this letter, submit your statement of intent
`to comply with 21 CFR 314.70(a)(4) to the address above, by fax to 301-847-8444, or
`electronically in eCTD format. For more information about submitting promotional materials in
`eCTD format, see the draft guidance for industry (available at:
`http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/U
`CM443702.pdf ).
`
`REPORTING REQUIREMENTS
`
`We remind you that you must comply with reporting requirements for an approved NDA
`(21 CFR 314.80 and 314.81).
`
`If you have any questions, contact Rajesh Venugopal, Senior Regulatory Project Manager, at
`(301) 796-4730.
`
`
`Sincerely,
`
`{See appended electronic signature page}
`
`
`
`Amna Ibrahim, MD
`Deputy Director
`Division of Oncology Products 1
`Office of Hematology and Oncology Products
` Center for Drug Evaluation and Research
`
`
`
`Enclosure(s):
`Content of Labeling
`
`Reference ID: 4152597
`
`

`

`---------------------------------------------------------------------------------------------------------
`This is a representation of an electronic record that was signed
`electronically and this page is the manifestation of the electronic
`signature.
`---------------------------------------------------------------------------------------------------------
`/s/
`----------------------------------------------------
`
`AMNA IBRAHIM
`09/14/2017
`
`Reference ID: 4152597
`
`(
`
`
`
`